Roles and causes of abnormal DNA methylation in gastrointestinal cancers

Asian Pacific Journal of Cancer Prevention

Volumn 7, Issue 2, 2006, Pages 177-185

  Suzuki, Hiromu ^a   Toyota, Minoru ^a   Sato, Hironobu ^a   Sonoda, Tomoko ^a   Sakauchi, Fumio ^a   Mori, Mitsuru ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Aging; Cimp; DNA methylation; Folate; Gastrointestinal cancer; Inflammation; Mthfr; Polymorphism; Tumor suppressor

Indexed keywords

FOLIC ACID;

AGING; CPG ISLAND; DNA METHYLATION; GASTROINTESTINAL TUMOR; GENE SILENCING; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

AGING; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FOLIC ACID; GASTROINTESTINAL NEOPLASMS; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION;

EID: 33748454508     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP (1998). Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res, 58, 5489-94.
2. Akino K, Toyota M, Suzuki H et al (2005). The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology, 129, 156-69.
3. Bagley P, Selhub J (1998). A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells. Proc Natl Acad Sci USA, 95, 13217-20.
4. Benito E, Stiggelbout A, Bosch FX et al (1991). Nutritional factors in colorectal cancer risk: a case-control study in Majorca. Int J Cancer, 49, 161-7.
5. Benito E, Cabeza E, Moreno V, Obrador A, Bosch FX (1993). Diet and colorectal adenomas: a case-control study in Majorca. Int J Cancer, 55, 213-19.
6. Bird AP, Wolffe AP (1999). Methylation-induced repression-belts, braces, and chromatin. Cell, 99, 451-4.
7. Botto LD, Yang Q (2000). 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol, 151, 862-77.
8. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet, 21, 103-7.
9. Chen J, Giovannucci E, Kelsy K et al (1996). A methylenetetrahydro-folate reductase polymorphism and the risk of colorectal cancer. Cancer Res, 56, 4862-4.
10. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R (1998). DNA hypomethylation leads to elevated mutation rates. Nature, 395, 89-93.
11. Corn PG, Summers MK, Fogt F et al (2003). Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis, 24, 47-51.
12. Dammann R, Li C, Yoon JH et al (2000). Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet, 25, 315-9.
13. Duthie SJ, Narayanan S, Sharp L et al (2004). Folate, DNA stability and colo-rectal neoplasia. Proc Nutr Soc, 63, 571-8.
14. Eden A, Gaudet F, Waghmare A, Jaenisch R (2003). Chromosomal instability and tumors promoted by DNA hypomethylation. Science, 300, 455.
15. Endoh M, Tamura G, Honda T et al (2005). RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer. Br J Cancer, 93, 1395-9.
16. Feinberg AP, Tycko B (2004). The history of cancer epigenetics. Nat Rev Cancer, 4, 143-53.
17. Fenech M, Aitken C, Rinaldi J (1998). Folate, vitamin B12, homocysteine status and DNA damage in young Australian adults. Carcinogenesis, 19, 1163-1171.
18. Friso S, Choi SW, Girelli D et al (2002). A commonmutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation status through an interaction with folate status. Proc Natl Acad Sci USA, 99, 5606-11.
19. Frosst P, Blom HJ, Milos R et al (1995). Candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet, 10, 111-113.
20. Giovannucci E, Rimm EB, Ascherio A et al (1995). Alcohol, lowmethionine - low-folatediets, and risk of colon cancer in men. J Natl Cancer Inst, 87, 265-73.
21. Giovannucci E, Stampfer MJ, Colditz GA et al (1993). Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst, 85, 875-84.
22. Giovannucci E, Stampfer MJ, Colditz GA et al (1998). Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med, 129, 517-24.
23. Goyette P, Sumner JS, Milos R et al (1994). Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet, 7, 195-200.
24. Herman JG, Baylin SB (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 349, 2042-54.
25. Hesson LB, Wilson R, Morton D et al (2005). CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene, 24, 3987-94.
26. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA (2001). Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res, 61, 3573-7.
27. Iwata N, Yamamoto H, Sasaki S et al (2000). Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene, 19, 5298-302.
28. Jacob RA, Gretz DM, Taylor PC et al (1998). Moderate folate depletion increases plasma homocysteine and decreases lymphocyte DNA methylationin postmenopausal women. J Nutr, 128, 1204-1212.
29. Jacques PF, Bostom AG, Williams RR et al (1996). Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation, 93, 7-9.
30. Jones PA, Baylin SB (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet, 3, 415-28.
31. Kaneto H, Sasaki S, Yamamoto H et al (2001). Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut, 48, 372-7.
32. Keku T, Millikan R, Worley K et al (2002). 5,10-methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. Cancer Epidemiol Biomarkers Prev, 11, 1611-21.
33. Kenyon SH, Nicolaou A, Gibbons WA (1998). The effect of ethanol and its metabolites upon methionine synthase activity in vitro. Alcohol, 15, 305-9.
34. Kim YI (1999). Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr Biochem, 10, 66-88.
35. Kim YI (2000). Methylenetetrahydrofolate reductase polymorphisms, folate, and cancer risk: a paradigm of genenutrient interactions in carcinogenesis. Nutr Rev, 58, 205-9.
36. Kinzler KW, Vogelstein B (1996). Lessons from hereditary colorectal cancer. Cell, 87, 159-70.
37. Kondo Y, Shen L, Yan PS, Huang TH, Issa JP (2004). Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci USA, 101, 7398-403.
38. Konings EJ, Goldbohm RA, Brants HA, Saris WH, van den Brandt PA (2002). Intake of dietary folate vitamers and risk of colorectal carcinoma; results from the Netherlands cohort study. Cancer, 95, 1421-33.
39. Kusano M, Toyota M, Suzuki H et al (2006). Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer, 106, 1467-79.
40. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A (1997). The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology, 112, 29-32.
41. Le Marchand L, Donlon T, Hankin JH et al (2002). B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control, 13, 239-48.
42. Ma J, Stampfer MJ, Giovannucci E et al (1997). Methylenetetrahydro-folate reductase polymorphism, dietary interactions and risk of colorectal cancer. Cancer Res, 57, 1098-102.
43. Ma J, Stampfer MJ, Christensen B et al (1999). A polymorphism of the methionine synthase gene: association with plasma folate, vitamin B12, homocyst(e)ine, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev, 8, 825-9.
44. Ma J, Stampfer MJ, Giovannucci E et al (1997). Methylenetetrahydro-folate reductase polymorphism, dietary interactions and risk of colorectal cancer. Cancer Res, 57, 1098-1102.
45. Magdinier F, Wolffe AP (2001). Selective association of the methyl CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia. Proc Natl Acad Sci USA, 98, 4990-5.
46. Molloy AM, Daly S, Mills JL et al (1997). Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet, 349, 1591-3.
47. Murai M, Toyota M, Suzuki H et al (2005). Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res, 11, 1021-7.
48. Narayanan S, McConnell J, Little J et al (2004). Interactions between two common variants C677T and A1298C in the methylene-tetrahydrofolate reductase gene and measures of folate metabolism and DNA stability (strandbreaks, misincorporated uraciland DNA methylation status). Cancer Epidemiol Biomarkers Prev, 13, 1-8.
49. Obata T, Toyota M, Satoh A et al (2003). Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. Clin Cancer Res, 9, 6410-8.
50. Oyama K, Kawakami K, Maeda K, Ishiguro K, Watanabe G (2004). The association between methylenetetrahydrofolate reductase polymorphism and promoter methylation in proximal colon cancer. Anticancer Res, 24, 649-54.
51. Park KS, Mok JW, Kim JC (1999). The 677>T mutation in 5,10-methylenetetrahydrofolate reductase and colorectal cancer risk. Genet Test, 3, 233-6.
52. Paz MF, Avila S, Fraga MF et al (2002). Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumours. Cancer Res, 62, 4519-24.
53. Porcelli B, Frost B, Rosi F et al (1996). Levels of folic acid in plasma and in red blood cells of colorectal cancer patients. Biomedical Pharmacotherapy, 50, 303-5.
54. Pufulete M, Al-Ghnaniem R, Leather AJ et al (2003a). Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology, 124, 1240-1248.
55. Pufulete M, Emery PW, Sanders TA (2003b). Folate, DNA methylation and colorectal cancer. Proc Nutr Soc, 62, 437-45.
56. Rampersaud GC, Kauwell GP, Hutson AD, Cerda JJ, Bailey LB (2000). Genomic DNA methylation decreases in response to moderate folate depletionin elderly women. Am J Clin Nutr, 72, 998-1003.
57. Rashid A, Issa JP (2004). CpG island methylation in gastroenterologic neoplasia: a maturing field. Gastroenterology, 127, 1578-88.
58. Samowitz WS, Albertsen H, Herrick J et al (2005). Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology, 129, 837-45.
59. Satoh A, Toyota M, Itoh F et al (2002). DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer, 86, 1817-23.
60. Sharp L, Little J (2004). Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol, 159, 423-43.
61. Slattery ML, Potter JD, Samowitz W et al (1999). Methylenetetrahy-drofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev, 8, 513-18.
62. Stern LL, Mason JB, Selhub J, ChoiSW (2000). Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev, 9, 849-853.
63. Suzuki H, Itoh F, Toyota M et al (1999). Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. Int J Cancer, 83, 309-13.
64. Suzuki H, Itoh F, Toyota M et al (2000). Inactivation of the 14-3-3 sigma gene is associated with 5' CpG island hypermethylation in human cancers. Cancer Res, 60, 4353-7.
65. Suzuki H, Gabrielson E, Chen W et al (2002). A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet, 31, 141-9.
66. Takai D, Jones PA (2002). Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA, 99, 3740-45.
67. Toyota M, Ahuja N, Ohe-Toyota M et al (1999a). CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA, 96, 8681-86.
68. Toyota M, Sasaki Y, Satoh A et al (2003). Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA, 100, 7818-23.
69. Toyota M, Ahuja N, Suzuki H et al (1999b). Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res, 59, 5438-42.
70. Toyota M, Ohe-Toyota M, Ahuja N, Issa JP (2000). Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA, 97, 710-5.
71. Tseng M, Murray SC, Kupper LL, Sandler RS (1996). Micronutrients and the risk of colorectal adenomas. Am J Epidemiol, 144, 1005-14.
72. van Engeland M, Weijenberg MP, Roemen GM et al (2003). Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res, 63, 3133-7.
73. van Rijnsoever M, Grieu F, Elsaleh H, Joseph D, Iacopetta B (2002). Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut, 51, 797-802.
74. Yi P, Melnyk S, Pogribna M et al (2000). Increase in plasma homocysteine associated with parallel increases in plasma Sadenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem, 275, 29318-23.
75. Yokoyama T, Sagara J, Guan X et al (2003). Methylation of ASC/ TMS1, a proapoptotic gene responsible for activating procaspase-1, in human colorectal cancer. Cancer Lett, 202, 101-8.